Article

HHS Decides Not to Leapfrog to ICD-11

Word of the new ICD-10 compliance deadline came as welcome news to many in the healthcare realm — just not everyone.

There remains a corner of the industry that publicly asked the Department of Health and Human Services (HHS) to consider other alternatives, most notably ICD-11, before mandating a new deadline.

Read the full story: http://bit.ly/NAp9st

Source: Healthcare Finance News

Related Videos
Dr Duke Appiah
Ajai Chari, MD
Shawn Griffin, MD, sitting for a video interview
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
John Michael O'Brien, PharmD, MPH
Kathi Henson, MBA, sitting for a video interview
Mike Fazio, Navista, Cardinal Health
Related Content
Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com.jpeg
May 1st 2025

NCODA Outlines New Patient-Centered Oncology Distribution Models

Pearl Steinzor
Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Screening for AMD | Image credit: RFBSIP - stock.adobe.com
May 1st 2025

Short-Term Improvements Seen in Patients With nAMD Switching to Faricimab

Julia Bonavitacola
Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and subretinal and intraretinal fluid after switching.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
The results offer some of the first glimpses into real-world findings of the JAK inhibitor momelotinib, which was approved in 2023. | Image credit: mdaros - stock.adobe.com
May 1st 2025

Real-World Findings Confirm Clinical Data on Momelotinib in MF With Anemia

AJMC Contributor
The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with myelofibrosis (MF) and anemia.
Two steps for success in value-based oncology care
May 1st 2025

Two steps for success in value-based oncology care

Mike Fazio, Head of Value-Based Care, Navista

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo